DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$4.13 USD
+0.09 (2.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.13 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
DMAC 4.13 +0.09(2.23%)
Will DMAC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DMAC
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Other News for DMAC
DiaMedica Therapeutics Upcoming Conference Participation
DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.03